Related Experiment Video
Updated: Feb 3, 2026

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
Published on: March 8, 2019
[THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA]
R Tabukashvili1, V Kapetivadze1, K Tchaava1
1Tbilisi, State Medical University, Department of Propedeutics of Internal Deseases, Georgia.
Insights
Combined therapy with Exforge and fibrates effectively lowers blood pressure and improves lipid profiles in hypertensive patients with dyslipidemia. This treatment strategy offers significant benefits for cardiovascular health management.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Hypertension and dyslipidemia are significant risk factors for cardiovascular disease.
- Combined therapy aims to address both conditions simultaneously for improved patient outcomes.
Purpose of the Study:
- To evaluate the clinical efficacy of combined therapy using Amlodipine/Valsartan (Exforge) with fibrates in hypertensive patients with dyslipidemia.
- To assess the impact on blood pressure control and lipid profile parameters.
Main Methods:
- A study involving 58 hypertensive patients (aged 40-65) with dyslipidemia, divided into three groups.
- Treatment regimens included Amlodipine with Fenofibrate, Exforge with Fenofibrate, and Exforge alone over a 4-month period.
- Parameters monitored included blood pressure, heart rate, BMI, and lipid profiles (Total Cholesterol, Triglycerides, HDL, LDL).
Main Results:
- Group 3 (Exforge alone) showed a significant reduction in systolic blood pressure (26.6%) and diastolic blood pressure (18.0%).
- This group also demonstrated significant improvements in lipid profiles, with decreased Total Cholesterol (-14.5%), Triglycerides (-15.9%), and LDL (-20.2%).
- Combined therapy with Exforge and fibrates proved effective in managing both hypertension and dyslipidemia.
Conclusions:
- Combination therapy involving Exforge and fibrates is a clinically effective strategy for hypertensive patients with dyslipidemia.
- This approach leads to substantial improvements in blood pressure control and lipid parameters, contributing to better cardiovascular risk management.
Abstract:
Purpose - studying of clinical efficiensy of the combined therapy (Amlodipin with Valsartan and fibrates) in hypertensive patients with dyslipidemia. Were studied 58 patients (40-65 years old) with hypertension (the level of arterial pressure was ≥140/90 and ≤180/110mm.Hg.RR). The patients have been divided into 3 groups: Group 1( n=18, middle age 55,8±5,9) were given Amlodipin 10 mg., Fenofibrates 200mg. (Lipantil); Group 2 (n=20, middle age 58,0±4,9) were given Exforge (Amlodipin 5mg./Valsartan 160mg.) and Lipantil 200mg.; Group3 (n=20, middle age 57,0±6,9) were given Exforge. Research duration- 4 months. Was done collection of anamnesis, calculation of BMI, Heart rate, Blood pressure. Before and after observation were investigated: lipid range, Total Cholesterol, Triglycerides, High Density Lipoproteins, Low Density Lipoproteins by using W.Friedwald's formula. After 4 month in group 3 was found significantly reduce of Blood Pressure, systolic- 26,6%, (р<0,001), and diastolic - 18,0%; Significantly improve Lipid range. Were decreased the levels of Total Cholesterol -14,5%, Triglycerides-15,9%, Low Density Lipoproteins -20,2%. The combined therapy by Exforge and fibrates provides effective decrease in levels of blood pressure and improvement in lipid range in hypertensive patients with dyslipidemia.
More Related Videos
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Hypertension IV: Drug Therapy and Lifestyle Modifications
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Hypertension I: Introduction
Hypertension II: Pathophysiology
Hypertension V: Nursing Management

